Results 131 to 140 of about 27,657 (222)

Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease

, 2011
Objective: To review the literature on the efficacy and safety of rosiglitazone and pioglitazone for the treatment of Alzheimer's disease (AD). Data Sources: Literature was accessed through MEDLINE (1948-August 2011 week 2) and EMBASE (1980-2011 week 32)
Alicia R Desilets, Benjamin W Miller, Kristine C Willett   +2 more
core   +1 more source

Obesity‐ and Glucose‐Dependent Differential Autophagy Marker Expression in Adipose Tissues and Adipocytes

Obesity Science &Practice, Volume 12, Issue 3, June 2026.
ABSTRACT Background Autophagy is an evolutionarily highly conserved process and plays an important role in cellular homeostasis and metabolism. In obesity and obesity‐associated insulin resistance, both enhanced and suppressed autophagy have been observed in adipose tissues (AT).
Edita Islami, Andreas Schmid, Daniel Steger, Sebastian Köhler, Andreas Schäffler, Thomas Karrasch   +5 more
wiley   +1 more source

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini, Hassan Valadbeigi, Seyedeh Mahdieh Khoshnazar, Saeed Khoshnood, Shahab Falahi, Delsuz Rezaee, Ali Hematian, Mohammad Hossein Haddadi   +7 more
wiley   +1 more source

Tubular Omega‐3 Fatty Acid Receptor FFAR4 Deficiency Aggravated Renal Aging and Chronic Kidney Disease

Aging Cell, Volume 25, Issue 6, June 2026.
This study illustrates that omega‐3 PUFAs with their receptor FFAR4 alleviate tubular senescence and fibrosis in aged and fibrotic kidneys. Furthermore, we indicate that tubular FFAR4 improves renal senescence via 15d‐PGJ2‐PPARγ‐Klotho signaling, and suppresses kidney fibrosis by senescent tubular cell‐driven fibroblast activation.
Letian Yang, Lei Tang, Jian Li, Dekai Liu, Chunchun Hu, Fan Guo, Lin Lin, Rongshuang Huang, Ping Fu, Liang Ma   +9 more
wiley   +1 more source

Groups—UCP1-shRNA in Rosiglitazone treated adipocytes.

, 2019
Groups—UCP1-shRNA in Rosiglitazone treated adipocytes.
Nicole Wen Mun Khor (7907894), Michael M. Swarbrick (7907897), Jenny E. Gunton (7907900)   +2 more
core   +1 more source

Hepatocellular injury in a patient receiving rosiglitazone. A case report.

, 2000
BACKGROUND: Rosiglitazone maleate (Avandia, SmithKline Beecham, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of type 2 diabetes. It acts primarily by increasing insulin sensitivity.
Arjomand, H, Al-Salman, J, Mittal, M, Kemp, D G   +3 more
core  

DEXA analysis of rosiglitazone-treated mice.

, 2015
DEXA analysis of rosiglitazone-treated mice.
Byung Chul Oh (801512), Ok-Hee Kim (801511), Hyae Gyeong Cheon (801513), Hye-Eun Choi (801508), Sangmee Hong (801510), Hyun Jeong Kwak (801507), Ju-Hee Kang (657393), Juyoung Kim (801509)   +7 more
core   +1 more source

Rosiglitazone Inhibits Proliferation, Motility, and Matrix Metalloproteinase Production in Keratinocytes

, 2004
This study was undertaken to evaluate the effects of thiazolidinediones (TZD) on keratinocyte proliferation, motility, and matrix metalloproteinase (MMP) production.
Lal, Ashish, Benson, Stephen C., Avery, Mitchell A., Chittiboyina, Amar, Kurtz, Theodore W., Pershadsingh, Harrihar A., Varani, James, Bhagavathula, Narasimharao, Nerusu, Kamalakar C., Ellis, Charles N., Ho, Christopher I.   +10 more
core   +1 more source

Effects of Rosiglitazone on Nitrolgycerin-induced Endothelial Dysfunction

, 2010
Sustained nitroglycerin (GTN) therapy impairs endothelial function in healthy volunteers and patients with cardiovascular disease, caused by an increase in vascular oxidative stress.
Perampaladas, Kumar
core   +1 more source

Rosiglitazone: Potential beneficial impact on cardiovascular disease

, 2003
Rosiglitazone, a potent member of the thiazolidinedione class of oral antidiabetic agents, reduces hyperglycaemia by improving insulin sensitivity - an important underlying factor in the development of both type 2 diabetes and its related cardiovascular ...
Viberti, G C
core